- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Jun 4, 2021
Distillery Therapeutics
Combining ULK1, ULK2 inhibition with anti-PD-1 therapy in NSCLC
DISEASE CATEGORY: Cancer
INDICATION: Lung cancer Inhibiting ULK1 and ULK2, which regulate autophagy, could increase the sensitivity of anti-PD-1 therapy in STK11-mutant non-small cell lung cancer
INDICATION: Lung cancer Inhibiting ULK1 and ULK2, which regulate autophagy, could increase the sensitivity of anti-PD-1 therapy in STK11-mutant non-small cell lung cancer
BioCentury | Jan 28, 2021
Product Development
Amgen keeps lead in KRAS race with pivotal lung cancer data, regulatory submissions
Expansive development program set sotorasib up to be first submitted for approval
BioCentury | Oct 27, 2020
Product Development
Mirati impresses with KRAS inhibitor response rates, potential biomarker
Data for MRTX849 support $926M follow-on as Mirati’s market cap crosses $10B
BioCentury | May 28, 2019
Distillery Therapeutics
Dual activation of JNK1 and JNK2 for STK11-deficient lung cancer
BioCentury | Sep 17, 2018
Tools & Techniques
AI code could speed cancer diagnosis, treatment decisions
BioCentury | Jun 16, 2018
Product Development
NSCLC disrupted
How companies are changing NSCLC plans based on ASCO data
BioCentury | Aug 4, 2016
Distillery Therapeutics
Therapeutics: Serine/threonine kinase 11 (STK11; LKB1)
Items per page:
1 - 10 of 24